Cargando…
Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
Today there are several options for the treatment of patients with malignant pleural mesothelioma (MPM). The therapeutic arsenal has expanded from only chemotherapy with or without surgery in selected cases to a variety of new compounds that target the malignant cell or its micro-environment. Immuno...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082258/ https://www.ncbi.nlm.nih.gov/pubmed/32206573 http://dx.doi.org/10.21037/tlcr.2020.01.16 |
_version_ | 1783508312810061824 |
---|---|
author | Disselhorst, Maria J. Baas, Paul |
author_facet | Disselhorst, Maria J. Baas, Paul |
author_sort | Disselhorst, Maria J. |
collection | PubMed |
description | Today there are several options for the treatment of patients with malignant pleural mesothelioma (MPM). The therapeutic arsenal has expanded from only chemotherapy with or without surgery in selected cases to a variety of new compounds that target the malignant cell or its micro-environment. Immunotherapy has been the latest achievement and now single arm and randomized studies are being presented. A renewed interest has occurred in the combination of surgery, chemotherapy and radiation therapy. In this review we present the available data on previous and running studies and try to give a recommendation how to select the best patient for the most optimal therapy. |
format | Online Article Text |
id | pubmed-7082258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-70822582020-03-23 Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma Disselhorst, Maria J. Baas, Paul Transl Lung Cancer Res Review Article Today there are several options for the treatment of patients with malignant pleural mesothelioma (MPM). The therapeutic arsenal has expanded from only chemotherapy with or without surgery in selected cases to a variety of new compounds that target the malignant cell or its micro-environment. Immunotherapy has been the latest achievement and now single arm and randomized studies are being presented. A renewed interest has occurred in the combination of surgery, chemotherapy and radiation therapy. In this review we present the available data on previous and running studies and try to give a recommendation how to select the best patient for the most optimal therapy. AME Publishing Company 2020-02 /pmc/articles/PMC7082258/ /pubmed/32206573 http://dx.doi.org/10.21037/tlcr.2020.01.16 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article Disselhorst, Maria J. Baas, Paul Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma |
title | Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma |
title_full | Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma |
title_fullStr | Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma |
title_full_unstemmed | Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma |
title_short | Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma |
title_sort | chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082258/ https://www.ncbi.nlm.nih.gov/pubmed/32206573 http://dx.doi.org/10.21037/tlcr.2020.01.16 |
work_keys_str_mv | AT disselhorstmariaj chemotherapyoptionsversusnoveltherapieshowshouldwetreatpatientswithmalignantpleuralmesothelioma AT baaspaul chemotherapyoptionsversusnoveltherapieshowshouldwetreatpatientswithmalignantpleuralmesothelioma |